|
CureVac
CureVac N.V. is a German biopharmaceutical company that develops therapies based on messenger RNA (mRNA). Legally domiciled in the Netherlands and headquartered in Tübingen, Germany, the company was founded in 2000 by Ingmar Hoerr (CEO), Steve Pascolo (CSO), Florian von der Mulbe (COO), Günther Jung, and Hans-Georg Rammensee. CureVac had approximately 240 employees in November 2015 and 375 in May 2018. At the beginning of the COVID-19 pandemic, CureVac was considered a beacon of hope for the development of a German vaccine. The federal government invested 300 million euros in the company. First, the CureVac vaccine was delayed due to minor problems, while the previously unknown BioNTech developed with Pfizer the very effective BNT162b2. In mid-2021, however, it became clear that the CureVac-vaccine was only 47 percent effective and is far away from approval. The company's focus is on developing vaccines for infectious diseases and drugs to treat cancer and rare diseases ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Curevac In Tübingen 02
CureVac N.V. is a German biopharmaceutical company that develops Nucleoside-modified messenger RNA, therapies based on messenger RNA (mRNA). Legally domiciled in the Netherlands and headquartered in Tübingen, Tübingen, Germany, the company was founded in 2000 by Ingmar Hoerr (CEO), Steve Pascolo (CSO), Florian von der Mulbe (COO), Günther Jung, and Hans-Georg Rammensee. CureVac had approximately 240 employees in November 2015 and 375 in May 2018. At the beginning of the COVID-19 pandemic, CureVac was considered a beacon of hope for the development of a German vaccine. The Fourth Merkel cabinet, federal government invested 300 million euros in the company. First, the CureVac vaccine was delayed due to minor problems, while the previously unknown BioNTech developed with Pfizer the very effective Pfizer–BioNTech COVID-19 vaccine, BNT162b2. In mid-2021, however, it became clear that the CureVac-vaccine was only 47 percent effective and is far away from approval. The company's ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
